Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TatD DNase domain containing 3 is a magnesium-dependent exonuclease that preferentially digests single-stranded DNA and RNA from the 3′- to 5′-end, with some apurinic/apyrimidinic endonuclease activity observed in vitro[1][2]. Structurally, it contains a TIM-barrel motif, which is common in enzymes with diverse catalytic activities[1]. Functionally, TATDN3 is implicated in DNA repair processes, including nucleotide excision and double-strand break repair, and has additional suggested roles in apoptotic DNA fragmentation[1]. Its activity is essential for maintaining genome integrity, particularly in response to oxidative DNA damage. The protein is evolutionarily conserved across species, underscoring its fundamental biological importance[1][3]. Specific disease associations, drug interactions, and clinical utility remain under investigation, with most current data supporting its general relevance to DNA repair and apoptosis[1][2][3][4].
Not established for specific drugs. Hypothetically, inhibitors would block exonuclease activity and interfere with DNA repair; activators could enhance genome stability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TatD DNase domain containing 3 (TATDN3).